Article

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

2015-01-01

Abstract

Meeting abstracts Immune checkpoint inhibition with anti–PD-1 monoclonal antibodies such as pembrolizumab has demonstrated robust, durable anti-tumor activity against many advanced malignancies. We analyzed immune-related gene expression profiles in pembrolizumab-treated patients with advanced

Full abstract shown under CC BY

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7273ff8c-1e4a-51a5-a880-97bf2e84ac6e
DOI: 10.1186/2051-1426-3-s2-p80
PMCID: PMC4645163

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumorsDOI 10.1186/2051-1426-3-s2-p80Read

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapySemantic proximity Read

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.Semantic proximity Read

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesSemantic proximity Read

Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable DiseaseSemantic proximity Read

The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor TypesSemantic proximity Read

Analysis of PD-1 related immune transcriptional profile in different cancer typesSemantic proximity Read

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read